Abstract
Sarcoidosis is defined as an inflammatory systemic disease; the characteristic morphological feature is the noncaseating granuloma. Typical finding in bronchoalveolar lavage (BAL) is a lymphocytic alveolitis with an increased CD4/CD8-quotient. A higher frequency of sarcoidosis in non-smokers (NS) than in smokers (S) has been reported. The influence of inhalative smoking on demographical data, lung function and results of BAL in prospectively selected patients with sarcoidosis was investigated. 111 NS (Sarcoidosis stage I/II+III 48/63) and 44 S (23/21) were included in the study. 16 patients without provable pulmonary disease (9 NS, 7 S) served as controls. Patients with sarcoidosis ware less often S than NS (28 vs. 72 %, p = 0,0001) Controls 44 vs. 56 %, p = 0,6 [χ2]). Sarcoidosis S were younger than NS (40,4 ± 11,9 vs. 45,6 ± 14,7 years, p = 0,009). There were no differences in the IVC (in % predicted). There was a negative effect of smoking on the course of the IVC (% predicted) with incremental age, not seen in the non smoking group (S vs. NS: r = -0,54, p = 0,001 vs. r = -0,13, p = 0,22). In BAL of Sarcoidosis S there was a lower concentration of albumin than of NS (in mg/dl), S vs. NS: 9,5 ± 5,9 vs. 14,5 ± 13,4, p = 0,012 and a trend to a less intensive lymphocytic alveolitis (in % of BAL-cells, S vs. NS: 29,2 ± 21,1 vs. 34,1 ± 18,6, p = 0,099). Influences of the smoking on the populations of T-lymphocytes could not be seen. (CD4/CD8-ratio S vs. NS 10,0 ± 11, 4 vs. 7, 2 ± 7, 1, p = 0, 25). In conclusion patients with sarcoidosis were more often NS than S. S were younger than NS. A protective effect of smoking on the course of lung function in sarcoidosis could be excluded. In the BAL S demonstrated a lower content of albumin and a trend to a less pronounced lymphocytosis and therefore a less pronounced alveolitis than NS. Influences of smoking on the distribution of the lymphocytic populations were not seen.
Literatur
-
1
Martinetti M, Tinelli C, Kolek V. et al .
“The sarcoidosis map”: a joint survey of clinical and immunogenetic findings in two European countries.
Am J Respir Crit Care Med.
1995;
152 (2)
557-564
-
2
American Thoracic Society/European Respiratory Society International .
Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias.
Am J Respir Crit Care Med.
2002;
165
277-304
-
3
Donaghy M, Rees A J.
Cigarette smoking and lung hemorrhage in glomerulonephritis caused by autoantibodies to glomerular basement membrane.
Lancet.
1983;
17 (2)
1390-1393
-
4
Murin S, Bilello K S, Matthay R.
Other smoking-affected pulmonary diseases.
Clin Chest Med.
2000;
21 (1)
121-137
-
5
Yamaguchi E, Okazaki N, Itoh A. et al .
Interleukin 1 production by alveolar macrophages is decreased in smokers.
Am Rev Respir Dis.
1989;
140 (2)
397-402
-
6
Wallace J M, Oishi J S, Barbers R G. et al .
Lymphocytic subpopulations profiles in bronchoalveoläre Lavage fluid and peripheral blood from tobacco and marijuana smokers.
Chest.
1994;
105 (3)
847-852
-
7
Drent M, Velzen-Blad H van, Diamant M. et al .
Relationship between presentation of sarcoidosis and T lymphocyte profile. A study in bronchoalveolar lavage fluid.
Chest.
1993;
104 (3)
795-800
-
8
Laan M, Qvarfordt I, Riise G C. et al .
Increased level of interleukin-16 in the airways of tobacco smokers: relationship with peripheral blood lymphocytes.
Thorax.
1999;
54(10)
911-916
-
9 Costabel U. Atlas der bronchoalveolären Lavage. Stuttgart, New York: Thieme 1994
-
10
Cigarette smoking and health. Official statement of the American Thoracic Society.
Am J Respir Crit Care Med.
1996;
153 (5)
861-888
-
11
Ström K E, Eklund A G.
Smoking does not prevent the onset of respiratory failure in sarcoidosis.
Sarcoidosis.
1993;
10 (1)
26-28
-
12
Valeyre D, Soler P, Clerici C. et al .
Smoking and pulmonary sarcoidosis: effect of cigarette smoking on prevalence, clinical manifestations, Alveolitis, and evolution of the disease.
Thorax.
2000;
43 (8)
516-524
1 MasterLAB Fa. Jaeger & Toennies, Höchberg
2 Olympus Optical Co. GmbH Hamburg
3 Topper 8, Fa. Johnson & Johnson, Norderstedt
4 K 800 Fa. Sysmex, Norderstedt
5 Cytospin 2, Fa. Shandon, Frankfurt a.M.
6 Dako, Hamburg
7 Dade Behring, Marburg
Dr. med. Johannes Schildge
St. Vincentius-Kliniken Karlsruhe gAG· Medizinische Klinik - Abteilung Pneumologie
Südendstraße 32
76137 Karlsruhe
eMail: johannes.schildge@vincentius-ka.de
URL: http://www.vincentius-ka.de
